T. Rowe Price Health Sciences' newest team members are settling in nicely, leading to an upgrade in its Morningstar Analyst Rating to Bronze from Neutral.
T. Rowe Price Health Sciences PRHSX
NAV / 1-Day Return
92.45
/
0.41
%
Total Assets
15.3 Bil
Adj. Expense Ratio
Adjusted Expense Ratio excludes certain variable investment-related expenses, such as interest from borrowings and dividends on borrowed securities, allowing for more consistent cost comparisons across funds.
0.760%
Expense Ratio
0.760%
Fee Level
Low
Longest Manager Tenure
4.47
years
Category
US Fund Health
Investment Style
Large GrowthMin. Initial Investment
2,500
Status
Open
TTM Yield
0.05%
Turnover
39%
Premium
Morningstar’s Analysis
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
Will PRHSX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable PRHSX’s performance objective and investment process is for both security selection and portfolio construction.
People Pillar
The People Pillar is our evaluation of the PRHSX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of PRHSX’s parent organization’s priorities and whether they’re in line with investors’ interests.
Upgraded as the team settles in.
